NCT01339299

Brief Summary

The study is a prospective, randomised, controlled, and non-blinded multi-center pilot study to evaluate endocrine efficacy of recombinant luteinizing hormone versus recombinant human chorionic gonadotropin administered during controlled ovarian stimulation for IVF/ICSI in normogonadotrophic women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2009

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2009

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

April 19, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 20, 2011

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

November 27, 2013

Completed
Last Updated

November 27, 2013

Status Verified

April 1, 2011

Enrollment Period

2.8 years

First QC Date

April 19, 2011

Results QC Date

September 25, 2013

Last Update Submit

September 25, 2013

Conditions

Keywords

COSARTInfertility

Outcome Measures

Primary Outcomes (1)

  • The Oestradiol Concentration on the Day of Ovulation Induction

    treatment day 10 to 14

Study Arms (2)

recombinant luteinizing hormone

EXPERIMENTAL

150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)

Drug: recombinant luteinizing hormone (r-LH)

recombinant human chorionic gonadotrofin

ACTIVE COMPARATOR

25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )

Drug: recombinant human chorionic gonadotropin (r-hCG)

Interventions

administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)

recombinant luteinizing hormone

administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)

recombinant human chorionic gonadotrofin

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women who plan to undergo IVF or ICSI treatment
  • Woman's age \> 18 years but ≤ 35 years
  • Regular menstrual cycle (25-34 days)
  • BMI 18 to 30 inclusive
  • Signed patient information and informed consent forms

You may not qualify if:

  • PCOS
  • More than 2 prior IVF/ICSI attempts
  • Diabetes mellitus, epilepsy, lever-, kidney-, heart- and metabolism disorders, according to the Investigator's assessment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fertility Clinic Skive regional Hospital

Skive, Denmark

Location

MeSH Terms

Conditions

Infertility

Interventions

Luteinizing HormoneChorionic Gonadotropin

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

Gonadotropins, PituitaryGonadotropinsPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPituitary Hormones, AnteriorPituitary HormonesPeptidesAmino Acids, Peptides, and ProteinsPlacental HormonesPregnancy ProteinsProteins

Results Point of Contact

Title
Prof, M.D. Peter Humaidan
Organization
Fertility Clinic Regional Hospital Skive

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. M.D. D.M.Sc.

Study Record Dates

First Submitted

April 19, 2011

First Posted

April 20, 2011

Study Start

October 1, 2009

Primary Completion

July 1, 2012

Study Completion

July 1, 2012

Last Updated

November 27, 2013

Results First Posted

November 27, 2013

Record last verified: 2011-04

Locations